Biological and analytical variation of clinical biomarker testing: Implications for biomarker-guided therapy

Current Heart Failure Reports

Volumn 10, Issue 4, 2013, Pages 434-440

  Wu, Alan H B ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Acute coronary syndromes; Analytical variation; Biological variation; Cardiovascular disease risk; Heart failure

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APOLIPOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE; DIURETIC AGENT; GALECTIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CREATINE KINASE BLOOD LEVEL; HEART FAILURE; HUMAN; LABORATORY TEST; LIVER FUNCTION TEST; PROTEIN BLOOD LEVEL; REFERENCE VALUE;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; DIAGNOSTIC TESTS, ROUTINE; DRUG MONITORING; HUMANS; REFERENCE VALUES; RISK ASSESSMENT; TROPONIN;

EID: 84888069990     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-013-0156-6     Document Type: Article

References (33)

1. Fraser CG. Biological variation: from principles to practice. Washington, DC: Am Assoc Clin Chem Press; 2001.
2. Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem. 2010;57:1303-6.
3. Wu AHB, Lu A, Todd J, Moecks J, Wians F. Short- and long-term biological variation in cardiac troponin I with a high-sensitivity assay: implications for clinical practice. Clin Chem. 2009;55:52-8.
4. Vasile VC, Saenger AK, Kroning JM, Klee GG, Jaffe AS. Biological variation of a novel cardiac troponin I assay. Clin Chem. 2011;58:1080-1.
5. Frankenstein L, Wu AHB, Hallermayer K, Wians Jr FH, Giannitsis E, Katus HA. Biological variation and reference change value of high-sensitivity troponin T in healthy individuals during short and intermediate follow-up periods. Clin Chem. 2011;58:1068-71.
6. Apple FS, Murakami MM, Wians FH, Ler R, Kaczmarek JM, Wu AHB. Short-term biological variation of cardiac troponin I measured with three high-sensitivity assays. Clin Chem. 2011;57:C-05.
7. Goldberg J, Iriate B, Prostko J, Frias E, Ravalico T, Hebbar S. Short and long-term biological variability of troponin I determined using the Architect stat high sensitivity troponin I assay. Clin Chem. 2011;57:C-04.
8. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551-67.
9. Vasile VC, Saenger AK, Kroning JM, Jaffe AS. Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56:1086-90.
10. •• Nordenskjold AM, Ahlstrom H, Eggers KM, et al. Short- and long-term individual variation in cardiac troponin in patients with stable coronary artery disease. Clin Chem. 2013;59:401-9. In addition to original data, this paper provides a review of the studies published to date on biological variation for cardiac troponin.
11. Wu AHB. Interpretation of high sensitivity cardiac troponin I results: reference to biological variability in patients who present to the emergency room with chest pain. Clin Chim Acta. 2009;401:170-4.
12. Aldous SJ, Richards AM, Cullen L, Than MP. Early dynamic change inhigh-sensitivity cardiac troponin T in the investigation of acute myocardial infarction. Clin Chem. 2011;57:1154-60.
13. Apple FS, Pearce LA, Smith SW, Kaczmarek JM, Murakami MAM. Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events. Clin Cnem. 2009;55:930-7.
14. Keller T, Zeller T, Ojeda F, et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA. 2011;305:2684-93.
15. •• Mueller M, Biener M, Vafaie M, Doerr S, et al. bsolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndromes and in patients with increased troponin in the absence of acute coronary syndromes. Clin Chem. 2012;58:209-18. Provides evidence that an absolute cutoff concentration for serial change in troponin may be superior to relative change.
16. Reichlin T, Schindler C, Drexler B, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med. 2012;172:1211.
17. Wu AHB, Smith AC, Mather JF, Duncan B, White CM, Ahlberg A, et al. Biological variation for NT-pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003;92:628-31.
18. Fokkema MR, Hermann Z, Muskiet FAJ, Moecks J. Reference change values for brain natriuretic peptides revisted. Clin Chem. 2006;51:1602-3.
19. Melzi d'Eril G, Tagnochetti T, Nauti A. Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. Clin Chem. 2003;49:1554-5.
20. Bruins S, Fokkema MR, Pomer JWP, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and B-type proBNP in patients with stable chronic heart failure. Clin Chem. 2004;50:2052-8.
21. Kim HN, Januzzi JL. Natriuretic peptide testing in heart failure. Circulation. 2011;123:2015-9.
22. Wu AHB. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biological variation in interpretation of results. Am Heart J. 2006;152:828-34.
23. Lok DJA, Van Der Meer P, Bruggink PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323-8.
24. Shah RV, Januzzi Jr JL. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep. 2010;7:9-14.
25. Wu AHB, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implications on interpretation of test results. Am Heart J. 2013;165:995-9.
26. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, et al. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest. 1999;59:491-500.
27. Kafonek SD, Derrgy CA, Bachorik PS. Biological variability of lipoproteins and apolipoproteins in patients referred to a lipid clinic. Clin Chem. 1992;38:864-72.
28. Braga F, Panteghini M. Biological variability of C-reactive protein: is the available information reliable. Clin Chim Acta. 2012;413:1179-83.
29. Pearson TA, Mensah GA, Alexander RW, et al. AHA/CDC scientific statement. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professions from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
30. Fraser CG. Test result variation and the quality of evidence-based guidelines. Clin Chim Acta. 2004;346:19-24.
31. Ridker PM, Danielson E, Fonseca FAH, et al. for the JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
32. •• Wu AHB, Christenson RH. Analytical and assay issues for use of cardiac troponin testing for risk stratification in primary care. Clin Biochem. 2013;12:969-78. A review of the merits for high-sensitivity cardiac troponin assays for potential use in primary care.
33. Wu AHB, Smith A, Wians F. Interpretation of creatine kinase and aldolase for statin-induced myopathy: reliance on serial testing based on biological variation. Clin Chim Acta. 2009;399:109-11.